LIPELLA PHARMACEUTICALS INC. Altman Z-Score
LIPO|Modified Z-Score (book value) based on FY2024 data
LIPELLA PHARMACEUTICALS INC.'s Altman Z-Score of -8.99 places the company in the "distress zone" used by the Altman model (below 1.23) for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
The score is below the 1.23 boundary used in the Altman model.
The Altman Z-Score uses 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2024 10-K filings.
5-Factor Decomposition
Working Capital / Total Assets
- Ratio
- 0.697
- Weight
- 0.717
- Contribution
- 0.500
Retained Earnings / Total Assets
- Ratio
- -5.737
- Weight
- 0.847
- Contribution
- -4.859
EBIT / Total Assets
- Ratio
- -1.900
- Weight
- 3.107
- Contribution
- -5.904
Book Equity / Total Liabilities
- Ratio
- 2.544
- Weight
- 0.420
- Contribution
- 1.069
Revenue / Total Assets
- Ratio
- 0.201
- Weight
- 0.998
- Contribution
- 0.200
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.697 | 0.717 | 0.500 |
| Retained Earnings / Total Assets | -5.737 | 0.847 | -4.859 |
| EBIT / Total Assets | -1.900 | 3.107 | -5.904 |
| Book Equity / Total Liabilities | 2.544 | 0.420 | 1.069 |
| Revenue / Total Assets | 0.201 | 0.998 | 0.200 |
| Total Z-Score | -8.99 | ||
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026
Z-Score Zones
Safe Zone - score above the 2.9 boundary used in the Altman model.
Grey Zone - score between the 1.23 and 2.9 boundaries used in the Altman model.
Distress Zone - score below the 1.23 boundary used in the Altman model.